Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma

Journal of Clinical Oncology

Volumn 33, Issue 20, 2015, Pages e84-e87

  Godbert, Yann ^a   De Figueiredo, Bénédicte Henriques ^a   Bonichon, Françoise ^a   Chibon, Frédéric ^a,b   Hostein, Isabelle ^a   Pérot, Gaëlle ^a   Dupin, Camille ^c   Daubech, Agnès ^c   Belleannée, Genevieve ^d   Gros, Audrey ^d   Italiano, Antoine ^a   Soubeyran, Isabelle ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

^c Laboratoire d'Anatomie et de Cytologie Pathologiques ^*  (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; ETOPOSIDE; THYROGLOBULIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR MARKER;

AGED; ARTICLE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; CERVICAL LYMPH NODE; CHEMORADIOTHERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; DYSPHAGIA; FEMALE; FIBERSCOPE ENDOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION ASSAY; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; LUNG LESION; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; MEDIASTINUM; MULTIPLE CYCLE TREATMENT; NECK TUMOR; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REAL TIME POLYMERASE CHAIN REACTION; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR VOLUME; ULTRASOUND; UNDIFFERENTIATED CARCINOMA; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; BIOPSY; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE; REMISSION; SECONDARY; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84940501179     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.6596     Document Type: Article

References (17)

1. Smallridge RC, Ain KB, Asa SL, et al: American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22:1104-1139, 2012
2. Kebebew E, Greenspan FS, Clark OH, et al: Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors. Cancer 103:1330-1335, 2005
3. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
4. Lim SM, Shin SJ, Chung WY, et al: Treatment outcome of patients with anaplastic thyroid cancer: A single center experience. Yonsei Med J 53:352-357, 2012
5. Ain KB, Egorin MJ, DeSimone PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion - Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587-594, 2000
6. Shimaoka K, Schoenfeld DA, DeWys WD, et al: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160, 1985
7. Smallridge RC, Marlow LA, Copland JA: Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17-44, 2009
8. Mooney CJ, Nagaiah G, Fu P, et al: A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19:233-240, 2009
9. Kloos RT, Ringel MD, Knopp MV, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684, 2009
10. Pennell NA, Daniels GH, Haddad RI, et al: A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323, 2008
11. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284, 1994
12. Minoo P, Wang HY: ALK-immunoreactive neoplasms. Int J Clin Exp Pathol 5:397-410, 2012
13. Allouche M: ALK is a novel dependence receptor: Potential implications in development and cancer. Cell Cycle 6:1533-1538, 2007
14. Mourali J, Bénard A, Lourenço FC, et al: Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 26:6209-6222, 2006
15. Hamatani K, Mukai M, Takahashi K, et al: Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. Thyroid 22:1153-1159, 2012
16. Hamatani K, Eguchi H, Ito R, et al: RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 68:7176-7182, 2008
17. Murugan AK, Xing M: Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 71:4403-4411, 2011